Nurix Therapeutics, Inc. NRIX
23.08
(0.57)
(2.41%)
as of 25 Sep
- Market cap
- $2.5B
- P/E
- 0.0×
Follow NRIX
| May '26 | Feb '26 | Nov '25 | Aug '25 | Older periods | |
|---|---|---|---|---|---|
| P/E ratio | 0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
| P/S ratio | 52.54 | 24.24 | 17.45 | 9.16 | |
| P/FCF ratio | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/Operating CF | (20.00) | (24.20) | (21.61) | (13.36) | |
| P/B ratio | 4.80 | 3.62 | 2.72 | 2.06 | |
| Price to Tangible BV | 4.80 | 3.62 | 2.72 | 2.06 | |
| EV/Sales | 40.48 | 16.71 | 10.39 | 4.04 | |
| EV/EBITDA | 0.00 | 0.00 | 0.00 | 0.00 | |
| EV/Operating CF | (5.07) | (4.61) | (3.50) | (1.47) | |
| EV/FCF | (4.89) | (4.41) | (3.31) | (1.40) | |
| Quick Ratio | 6.16 | 5.86 | 6.86 | 5.21 | |
| Current Ratio | 6.34 | 6.01 | 7.02 | 5.35 | |
| Net Debt/EBITDA | 4.91 | 6.09 | 6.68 | 4.96 | |
| Debt/Assets | 0.00% | 0.00% | 0.00% | 0.00% | |
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | |
| Asset Turnover | 0.07 | 0.11 | 0.12 | 0.16 | |
| Operating CF/Net income | 1.08 | 0.82 | 0.87 | 0.66 | |
| Capex/Depreciation | (0.50) | (0.28) | 0.90 | (0.54) | |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 | |
| Research and Development Expense of Revenue | 969.29% | 1,345.76% | 611.50% | 1,090.96% | |
| Selling, General and Administrative Expense of Revenue | 172.44% | 233.69% | 100.52% | 166.70% | |
| Intangible Assets out of Total Assets | 0.00 | 0.00 | 0.00 | 0.00 | |
| Share Based Compensation of Revenue | 125.93% | 150.42% | 66.92% | 123.79% | |
| Graham Net Nets | 0.17 | 0.23 | 0.31 | 0.38 | |
| Graham Number | 0.00 | 0.00 | 0.00 | 0.00 | |
| Earnings Yield | (19.84%) | (19.99%) | (17.98%) | (32.60%) | |
| Free Cash Flow Yield | (15.76%) | (15.62%) | (17.98%) | (31.48%) | |
| Revenue per Share | 0.08 | 0.06 | 0.16 | 0.09 | |
| Operating CF per Share | (0.87) | (0.65) | (0.78) | (0.68) | |
| Capex per Share | (0.02) | (0.01) | (0.06) | (0.03) | |
| Free Cash Flow per Share | (0.89) | (0.66) | (0.84) | (0.71) | |
| Cash per Share | 3.99 | 4.91 | 6.84 | 5.10 | |
| Shareholders Equity per Share | 3.62 | 4.37 | 6.22 | 4.42 | |
| Interest Debt per Share | 0.00 | 0.00 | 0.00 | 0.00 | |
| Book value per Share | 3.62 | 4.37 | 6.22 | 4.42 | |
| Free Cash Flow | (98.51) | (72.96) | (72.96) | (60.10) | |
| Working Capital | 384.46 | 462.20 | 520.35 | 358.25 | |
| Capital Expenditures | (1.94) | (1.04) | (5.13) | (2.71) | |
| Net Current Asset Value | 323.57 | 399.16 | 457.43 | 290.38 | |
| EV/EBIT | 0.00 | 0.00 | 0.00 | 0.00 | |
| Capex to Sales | 0.21 | 0.17 | 0.38 | 0.34 | |
| Net Profit Margin | (990.10%) | (1,394.34%) | (576.13%) | (1,094.77%) | |
| Price to Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
| Average Payables | 9.08 | 9.35 | 11.35 | 6.26 | |
| Average Assets | 563.55 | 625.59 | 678.74 | 518.04 | |
| Average Common Equity | 425.12 | 480.91 | 532.87 | 374.55 |
Columns are period end dates